Orion Corporation and Newel Health (?Newel?) have entered into a license agreement regarding ODD-403 (?Rohkea?), a digital therapeutic (DTx) developed by Orion for patients suffering from chronic pain and particularly from fear of movement and re-injury. Under the terms of the agreement, Newel will have the exclusive global rights to develop, manufacture and commercialise ODD-403. Orion is entitled to receive royalty from the sales of the product as well as sales milestone payments.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.85 EUR | +1.30% | +10.65% | -8.71% |
Apr. 26 | Orion Corporation Announces Appointments to Nomination Committee | CI |
Apr. 25 | Transcript : Orion Oyj, Q1 2024 Earnings Call, Apr 25, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.71% | 5.38B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ORNBV Stock
- News Orion Oyj
- Orion Corporation and Newel Health Enter into Licensing Agreement for Digital Therapeutic(DTx) ODD-403 (?Rohkea?) in pain